Form 8-K · Current report
AbbVie 8-K, filed Sep 3, 2026
- Filed
- CIK
- 0001551152
- Accession no.
- 0001104659-26-104940
Summary
AbbVie completed its acquisition of Apogee Therapeutics for $135.11 per share in cash, an equity value of roughly $10.9 billion, with Apogee now part of AbbVie and its stock delisted from Nasdaq. AbbVie CEO Robert A. Michael said the deal strengthens the company's immunology pipeline, while AbbVie reaffirmed its 2026 full-year and third-quarter adjusted diluted EPS guidance.
Key points
- Apogee shareholders received $135.11 per share in cash, a total equity value of about $10.9 billion, and Apogee stock ceased trading on Nasdaq before market open on Sept. 3, 2026.
- Apogee's lead asset, zumilokibart (APG777), is a half-life extended anti-IL-13 monoclonal antibody in late-stage development for atopic dermatitis; APG273 combines it with the anti-TSLP antibody APG333 for asthma.
- AbbVie reaffirmed 2026 full-year adjusted diluted EPS guidance of $13.87-$14.07 and third-quarter guidance of $3.84-$3.88.
- AbbVie expects the acquisition to reduce adjusted diluted EPS by $0.14 in 2026 and about $0.46 in 2027, with accretion beginning in 2032.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 7.01 Regulation FD Disclosure On September 3, 2026, AbbVie Inc. (the “Company”) issued a press release announcing the completion of its acquisition of Apogee Therapeutics, Inc. The press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01, including the exhibit referenced herein and attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.